You just read:

Sales of Revlimid and the Launch of Several Premium-Priced Emerging Therapies Will Drive Robust 7.2 Percent Annual Growth in the Multiple Myeloma Drug Market

News provided by

Decision Resources

Dec 06, 2010, 11:22 EST